Market research
GOV.F Insulet Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- 24.86
- Analyst target
- 290.41
- Dividend yield
- Not available
- Beta
- 1.08
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US45784P1012
- Market cap
- 8B
- P/E ratio
- 24.86
- Analyst target
- 290.41
- Dividend yield
- Not available
- Beta
- 1.08
About
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GOV.F discussion.
5 years, 5 months ago
Insulet Corporation is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 19.1.
Insulet Corporation's total revenue rose by 17.5% to $246M since the same quarter in the previous year.
Its net income has dropped by 444.2% to $-17M since the same quarter in the previous year.
Finally, its free cash flow fell by 1287.0% to $-42M since the same quarter in the previous year.
Based on the above factors, Insulet Corporation gets an overall score of 3/5.